Lecanemab
1 paper
- 1 on aging of 14 trials, 2 with no results posted
- 9 of 14 trials sponsored by its developers
Trials
1 on aging of 14On aging
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Phase 3Active, not recruiting
Approved
6 Jan 2023Dementia, mild cognitive impairment
15 Apr 2025Cognitive Dysfunction, Alzheimer Disease, Dementia, mild cognitive impairment, amyloid pathology
29 Aug 2025Dementia, mild cognitive impairment
Repurposing
Preclinical Alzheimer's disease
Phase 3Active, not recruiting1 trial
Every condition in trials
Early preclinical alzheimer disease
Phase 3Active, not recruiting1 trial
Readouts due
- 31 Dec 2026
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Phase 3Active, not recruiting
Development
- Companies
- EisaiPhase 3early Alzheimer's disease
Trial sponsors
Company6 trialsPhase 34,487 people
First Affiliated Hospital of Wenzhou Medical University
1 trialPhase 4200 people
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
1 trialPhase 4100 people
Washington University School of Medicine
3 trialsPhase 3727 people
Zhejiang Provincial People's Hospital
1 trialPhase 360 people
1 trialEarly phase 120 people
1 trialEarly phase 115 people